CrystalGenomics, Inc (083790) Fair Value & Analysis
Healthcare · KR · Market cap 67.2B KRW
Fair value as of: Jul 5, 2026
From 3 valuation models · updated today
Fair value updated Jul 5, 2026 — revised from 11,697 KRW to 899.93 KRW (−92.3%) since Jun 24, 2026. Share price +0.8% over the past month.
Price vs Fair Value (12 months)
12‑month range 779.00 KRW – 1,979 KRW · fair‑value band 383.51 KRW – 1,674 KRW · the 1,000 KRW price screens above the 899.93 KRW fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
CrystalGenomics, Inc (083790) currently trades at 1,000 KRW, while our model-based Fair Value estimate is 899.93 KRW — implying the stock looks roughly 10.0% overvalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, CrystalGenomics, Inc generated revenue of 45.0B KRW at a net margin of -64.6%. Revenue declined 0.8% year over year. Net debt stands at 32.5B KRW. Fundamentals as of Jul 5, 2026
Our scenario range runs from 383.51 KRW (bear case) to 1,674 KRW (bull case); at 1,000 KRW, the current price sits within that range. The share trades about 50% below its 52-week high and 32% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at -10%, 083790 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CrystalGenomics, Inc reported revenue of 27.4B KRW in FY2025 versus 42.4B KRW in FY2021, a compound −10.3%/yr. Reported net income was −3.5B KRW in FY2025.
Is 083790 fairly valued? → Check now
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ST Pharm Co 237690 | 115,900 KRW | 61,182 KRW | -47% |
| NatureCell Co 007390 | 33,950 KRW | 901.89 KRW | -97% |
| Oscotec Inc 039200 | 38,950 KRW | 34,117 KRW | -12% |
| DongKook Pharmaceutical Co 086450 | 20,100 KRW | 32,962 KRW | +64% |
| Kolon Life Science Inc 102940 | 45,000 KRW | 37,195 KRW | -17% |
| Komipharm International Co 041960 | 8,370 KRW | 543.06 KRW | -94% |
| BINEX Co 053030 | 7,940 KRW | 4,024 KRW | -49% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 22,700 KRW | 49,475 KRW | +118% |
| Vivozon Pharmaceutical Co 082800 | 4,045 KRW | 1,992 KRW | -51% |
| EURO EURO | 1.07 PHP | 0.7800 PHP | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CrystalGenomics, Inc (083790) undervalued?
What is the fair value of 083790?
What is the quality score of 083790?
What is the revenue of CrystalGenomics, Inc (083790)?
What is the net profit margin of 083790?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.